Lundbeck gets U.S. approval for epilepsy drug for children


COPENHAGEN, Oct 28 (Reuters) - Danish pharmaceutical groupLundbeck has won approval in the United States of itsepilepsy drug, Sabril, to be used in children aged 10 years andolder.

Lundbeck said in a statement on Monday the United StatesFood and Drug Administration (FDA) had approved Sabril as anadd-on therapy for the treatment of refractory complex partialseizures in children who have inadequately responded to severalother treatments.

View Comments (0)